Lung tumors (primary lung cancer and metastatic lung cancer)
Conditions
Interventions
Test group:Standard treatment plus electrocooling ablation system
Standard treatment group:Standard treatment of lung tumors (clinical guidelines for the treatment of primary lung cancer and metastatic lung cancer)
Control group:Standard treatment plus cryosurgery system
Sponsors
Dongfang Hospital Beijing University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1) Age 18 to 85 years old (including 18 and 85 years old), both sexes; 2) Patients with clearly diagnosed primary lung cancer or metastatic lung cancer, with the number of unilateral lung lesions = 3, target lesions measurable, 1 cm < target lesion < 6 cm, requiring ablative surgical treatment; 3) Those who cannot tolerate surgical resection or refuse it; 4) ECOG physical status score 0~2; 5) Voluntary participation with the free will of the subject or legal representative, and signed informed consent form.
Exclusion criteria
Exclusion criteria: 1) Those with small cell lung cancer; 2) Those with tumors combined with infectious or radiological inflammation and large ipsilateral pleural effusions; 3) Those with impaired pulmonary function due to severe lung disease with 150 mmHg or diastolic blood pressure (DBP) > 95 mmHg; 9) Those with uncontrollable arrhythmias, with episodes of myocardial infarction within six months; 10) Expected survival < 3 months; 11) Pregnant and lactating women and those who plan to become pregnant within one year; 12) Those with mental illness, impaired consciousness and inability to cooperate with treatment; 13) Those who participate in other clinical trials within one month; 14) Those who, in the opinion of the investigator, are not suitable to participate in this clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficiency at 3 months after tumor ablation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Efficiency at 1,3, 6 and 12 months after ablation;Immediate efficacy after ablation;Changes in CT values after ablation;Disease control rates at 1, 3, 6, and 12 months after ablation;Local recurrence rates at 1, 3, 6, and 12 months after ablation;Serum tumor marker test: CEA, CYFRA21-1, SCC;ECOG Rating;Overall survival rate at 1 year after surgery; | — |
Countries
China
Contacts
Public Contactquanwang li
Dongfang Hospital Beijing University of Chinese Medicine
Outcome results
None listed